No abstract

Objectives. To determine the outcome predictors of in-hospital mortality in acute total occlusion of the left main coronary artery (ATOLMA) patients referred to emergent angioplasty and to describe the clinical presentation and the long-term outcome of these patients. Background. ATOLMA is an uncommon angiographic finding that usually leads to a catastrophic presentation. Limited and inconsistent data have been previously reported regarding true ATOLMA, yet comprehensive knowledge remains scarce. Methods. This is a multicenter retrospective cohort that includes patients presenting with myocardial infarction due to a confirmed ATOLMA who underwent emergency percutaneous coronary intervention (PCI). Results. In the period of the study, 7930 emergent PCI were performed in the five participating centers, and 46 of them had a true ATOLMA (0.58%). At admission, cardiogenic shock was present in 89% of patients, and cardiopulmonary resuscitation was required in 67.4%. All the patients had right dominance. Angiographic success was achieved in 80.4% of the procedures, 13 patients (28.2%) died during the catheterization, and the in-hospital mortality rate was 58.6% (27/46). At one-year and at the final follow-up, 18 patients (39%) were alive, including four cases successfully transplanted. Multivariate analysis showed that postprocedural TIMI flow was the only independent predictor of in-hospital mortality (OR 0.23, (95% CI 0.1–0.36), p<0.001). Conclusions. Our study confirms that the clinical presentation of ATOLMA is catastrophic, presenting a high in-hospital mortality rate; nevertheless, primary angioplasty in this setting is feasible. Postprocedural TIMI flow resulted as the only independent predictor of in-hospital mortality. In-hospital survivors presented an encouraging outcome. ATOLMA and left dominance could be incompatible with life.

Background Spontaneous coronary artery dissection (SCAD) and Takotsubo syndrome (TTS) constitute two relatively common nonatherosclerotic causes of acute coronary syndrome particularly frequent in women. Methods This study sought to compare the baseline clinical and angiographic characteristics and in-hospital outcomes of patients from two large prospective registries on SCAD and TTS (the prospective nation-wide Spanish SCAD Registry and a prospective single-center TTS registry). Results A total of 318 SCAD and 106 TTS consecutive patients were included. Most patients in both groups (88%) were women. Patients in the TTS group were older [74 (interquartile range, IQR 67–81) vs. 53 years-old (IQR 47–60), P < 0.001] and presented a higher prevalence of cardiovascular risk factors. Precipitating triggers were more frequent in TTS (56% vs. 42%, P = 0.009) but emotional stress was more common in the SCAD group (25% vs. 15%, P = 0.037). TTS patients showed a reduced release of cardiac biomarkers but had more severe left ventricular dysfunction (ejection fraction <50%: 73% vs. 12%, P < 0.001). In-hospital major adverse cardiovascular events occurred more frequently in TTS patients (12% vs. 4.7%, P < 0.001). Notably, TTS patients showed more frequently congestive heart failure (10% vs. 0.6%, P < 0.001), atrial fibrillation (11% vs. 1%, P < 0.001) and had a higher all-cause in-hospital mortality (5.7% vs. 1.3%, P = 0.032). Conclusion TTS patients are older and present a higher prevalence of some cardiovascular risk factors than patients with SCAD. TTS is linked to a worse in-hospital prognosis with higher mortality.

Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus, reduced left ventricular ejection fraction and chronic kidney disease. However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients undergoing TAVI.

Background In patients with multi-vessel disease presenting with ST elevation myocardial infarction (STEMI), the efficacy and safety of ischemia-guided, vs routine non-culprit vessel angioplasty has not been adequately studied. Methods We conducted an international, randomized, non-inferiority trial comparing ischemia-guided non-culprit vessel angioplasty to routine non-culprit vessel angioplasty, following primary PCI for STEMI. The primary outcome was the between-group difference in percent ischemic myocardium at follow-up stress MPI. All MPI images were processed and analyzed at a central core lab, blinded to treatment allocation. Results In all, 109 patients were enrolled from nine countries. In the ischemia-guided arm, 25/48 (47%) patients underwent non-culprit vessel PCI following stress MPI. In the routine non-culprit PCI arm, 43/56 (77%) patients underwent angioplasty (86% within 6 weeks of randomization). The median percentage of ischemic myocardium on follow-up imaging (mean 16.5 months) was low, and identical (2.9%) in both arms (difference 0.13%, 95%CI − 1.3%–1.6%, P < .0001; non-inferiority margin 5%). Conclusion A strategy of ischemia-guided non-culprit PCI resulted in low ischemia burden, and was non-inferior to a strategy of routine non-culprit vessel PCI in reducing ischemia burden. Selective non-culprit PCI following STEMI offers the potential for cost-savings, and may be particularly relevant to low-resource settings. (CTRI/2018/08/015384).

No abstract

No abstract

Background Percutaneous coronary intervention (PCI) in spontaneous coronary artery dissection (SCAD) should be reserved for cases presenting with ongoing extensive ischaemia. Bioresorbable scaffolds (BVS) have emerged as an alternative to avoid permanent stenting, an especially attractive concept for this clinical scenario. However, data of late angiographic outcome of this device in SCAD is lacking. Purpose To evaluate the long-term angiographic outcome of BVS in the setting of SCAD using computed tomography coronary angiography (CTCA) Methods In this multicentre prospective study, high-risk SCAD patients treated with BVS were scheduled for a follow-up CTCA at least 2 years from implantation date. Acquisition was performed according to the current recommendations. All the studies were analysed in a central core laboratory by an independent level 3 expert in CTCA blinded to the clinical and angiographic results. For this purpose, a dedicated software for coronary analysis was used to quantify coronary stenosis and evaluate coronary wall. Results Thirty-four BVS were implanted in 15 SCAD patients (51±12 years-old; 87% female) from 7 different centres in Spain and United Kingdom. The most common presentation was STEMI (n=9, 60%). Target vessels included 11 left anterior descending arteries (73.3%), 3 right coronary arteries (20%) and 1 left circumflex coronary artery (6.7%). One patient received target lesion revascularisation due to scaffold shrinkage in a proximal right coronary artery at 13 months. CTCA was performed 2.4±0.7 years after BVS implantation. No scaffold thrombosis or significant stenosis were detected. Patency of all scaffolds was confirmed with a median luminal area of 5.52 mm2 (IQR: 3.74–6.95) and median stenosis of 11% (IQR: 4–15%). Regarding coronary wall tissue characterization of segments with BVS, there was 32±9.3% of plaque burden and a median plaque volume of 45.3 mm3 (IQR: 26.6–61.9). The most common component of the plaque was fibrous (85±9.4%). Compared to the proximal reference segments, BVS showed more plaque burden (32.2% vs 25.3%; p=0.017) and fibrous percentage (84.7% vs 75.1%; p=0.004) whereas less fibrofatty (6 vs 4.8 mm3; p=0.007) and necrotic volume (0.4 vs 1.2 mm3; p=0.029). BVS segments showed lower absolute minimal luminal area (5.5 vs 8.9 mm2; p=0.004) and diameter (2.7 vs 3.4 mm; p=0.004) compared to the reference segment; however, non-significant differences were seen in percentage stenosis, in keeping with normal vessel tapering. Conclusions In this series of SCAD treated with BVS, scaffolds showed a satisfactory late angiographic outcome, with no significant restenosis and an excellent minimal luminal area and optimal coronary wall healing observed. Funding Acknowledgement Type of funding source: None